Alerta

TARGETING NANOSCALE PARTICLE, TARGETING CELL, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: EP4628071A1

The invention discloses a targeted nanoscale particle, a targeted cell, a preparation method therefor, and use thereof. The targeted nanoscale particle is bound to the outer surface of the targeted cell, and is composed of a plurality of proteins interconnected via a first binding site. The targeted nanoscale particle further comprises a second binding site, and is bound to the outer surface of a target cell via the second binding site. In an exemplary embodiment, the targeted nanoscale particle can promote the interaction between the two types of cells by simultaneously binding to a chimeric antigen receptor T cell and a leukemia cell, thereby promoting the recognition and killing of the leukemia cell by the chimeric antigen receptor T cell. In addition, the internal cavities of the proteins in the targeted nanoscale particle provide space for loading of a chemotherapeutic drug, thus realizing the combination therapy of the chimeric antigen receptor T cell and other therapies while loading the drug.

BISPECIFIC ANTIBODIES AGAINST CANINE CD3 AND CD20

Resumen de: MX2025006274A

This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.

COMPOSITIONS AND METHODS FOR TREATING HUMAN PAPILLOMAVIRUS INFECTIONS

Resumen de: US2024342163A1

The invention provides compositions, compounds, formulations, and methods for treating HPV infections including pre-malignant infections and cancer. Compounds that covalently bind to the HPV E6 protein are disclosed.

VACCINES CONTAINING NOVEL NANOPARTICLE SCAFFOLDS

Resumen de: AU2023399881A1

The present invention provides novel engineered nanoparticle scaffold sequences that are derived from the 13-01 protein. Relative to the known 13-01 protein or variants thereof, the novel 13-01 derived scaffold sequences of the invention contain an extended N-terminal helix. Also provided in the invention are vaccine constructs that contain various immunogenic proteins displayed on the novel nanoparticle scaffold sequences described herein. The vaccine constructs of the invention include, e.g., nanoparticles displaying tandem repeats of influenza M2e proteins or HCV E2 core proteins.

SYNTHETIC SINGLE-STRANDED DNA MOLECULES AND METHODS OF PRODUCING AND USING THE SAME

Resumen de: AU2023406947A1

The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.

TARGETING GPR158 (MGLYR) WITH NANOBODIES FOR THERAPEUTIC BENEFITS

Resumen de: WO2024118636A1

The invention provides antibodies that specifically bind GPR158 and inhibit GAP activity of GPR158 via RGS7/ Gβ5. The antibodies are useful in the diagnosis and treatment of affective disorders, mood disorders, and brain disorders.

COMPOSITIONS AND METHODS FOR MAKING AND USING POLYMER-COATED NANOCAPSULES FOR TARGETED PHARMACEUTICAL AGENT DELIVERY

Resumen de: WO2024118638A2

Embodiments of the present disclosure provide novel compositions and methods for making and using polymer-coated nanocapsules. In certain embodiments, compositions and methods are disclosed for embedding at least one agent in a liquid fatty acid composition to form an inner core of the polymer-coated nanocapsule and coating the at least one agent-containing liquid fatty acid composition inner core with polymer to form at least one coating layer of polymer that further includes at least one positively charged surfactant (e.g., cationic surfactant), forming polymer-coated nanocapsules. In certain embodiments, the at least one positively charged surfactant binds to at least one targeting agent for directed use of the polymer-coated nanocapsules.

SYNTHETIC SINGLE STRANDED NUCLEIC ACID COMPOSITIONS AND METHODS THEREOF

Resumen de: AU2023406947A1

The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.

NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME

Resumen de: WO2024119037A1

Provided herein are an ionizable lipid compound, a lipid nanoparticle comprising the ionizable lipid compound, a composition comprising an mRNA formulated in the lipid nanoparticle, and a method of delivering an mRNA to a subject or a cell by administering the composition including an mRNA formulated in the lipid nanoparticle to the subject or cell.

NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME

Resumen de: AU2023406321A1

The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.

LONG NON-CODING RNA LIPTER PRESERVES LIPID METABOLISM OF THE HUMAN HEART

Resumen de: WO2024118378A1

Compositions and methods are disclosed for treating metabolic syndrome-associated heart disease cardiomyopathy and/or heart failure, wherein the method comprises the step of increasing the concentration of LIPTER RNA in the cardiomyocytes of said patient.

PHOSPHATIDYLAMINE COMPOUND COMPRISING MULTIPLE TERTIARY AMINO GROUP STRUCTURES, AND COMPOSITION AND USE THEREOF

Resumen de: EP4628494A1

A phosphatidylamine compound including a plurality of tertiary amino group structures and the composition and use thereof are provided. The phosphatidylamine compound is a phospholipid compound including two or more tertiary amino group structures, the structure of which is represented by the following formula (I), where, the definition of each substituent is detailed in the instructions. The compound works together with other lipid components such as cholesterol, DSPC/DOPE, DMG-PEG2000, and other helper lipids to form lipid nanoparticles (LNPs), which may be used for efficient delivery of drug molecules such as nucleic acids (siRNA, mRNA, pDNA), thereby realizing diagnosis and treatment of diseases such as cancer, fibrosis (e.g., liver, lung, kidney).

STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF

Resumen de: EP4628496A1

A steroid-cationic lipid compound as represented by formula (I). The LNP prepared from the compound can deliver a bioactive substance to a target cell or organ in an effective and stable manner, and the mRNA LNP prepared from the compound has good levels of stability and transfection efficiency, and can trigger a relatively high specific antibody response and cellular immune response in an animal.

STABLE TOPICAL NANOEMULSION COMPRISING MEGLUMINE ANTIMONIATE AND AMPHOTERICIN B FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS

Resumen de: EP4628102A2

The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient. Another objective of the present invention is to provide a topical, fixed-dose formulation containing a combination of antileishmanial compounds that has sufficient efficacy and safety to be used in the treatment of cutaneous leishmaniasis.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS AND LIPID-ANCHORED POLYMERS

Resumen de: WO2024119103A1

Provided herein are lipid nanoparticles (LNPs) comprising a therapeutic nucleic acid (TNA) and uses thereof. The LNPs comprise an ionizable lipid; a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, and do not comprise a helper lipid.

LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS

Resumen de: WO2024119098A1

The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.

SURFACE MODIFIED CARBON NANOTUBES AND USES THEREOF

Resumen de: AU2023401698A1

Provided herein are pharmaceutical compositions comprising surface functionalized carbon nanotube and an active agent. The active agent can be attached to the carbon nanotube covalently or noncovalently. Also provided are methods of preparing the pharmaceutical compositions and methods of use thereof.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS, IONIZABLE LIPIDS, STEROLS, LIPID ANCHORED POLYMERS AND HELPER LIPIDS, THEIR USES

Resumen de: AU2023406303A1

Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.

STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: AU2023406483A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,

GOLD NANOZYME COMPRISING GLYCOL CHITOSAN AND GOLD PARTICLES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE COMPRISING SAME

Resumen de: EP4628070A1

One aspect according to the present invention relates to: a gold nanozyme including glycol chitosan and gold particles; and a pharmaceutical composition for preventing or treating inflammatory bowel disease, the composition comprising the gold nanozyme. The gold nanozyme and the pharmaceutical composition comprising same according to one aspect of the present invention was found to inhibit the expression of inflammatory factors, inhibit the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) inside cells, and reduce the production of nitric oxide (NO) inside cells. In addition, the gold nanozyme was found to inhibit the secretion of Hight Mobility Group Box 1 (HMGB1) when further including glycyrrhizin. In addition, the gold nanozyme and the composition comprising same were found to enable the recovery of the length, weight, etc., of damaged intestines, and thus can be used in the inflammatory bowel disease prevention and/or treatment industry/market.

一种外泌体包覆的共负载金纳米颗粒和抗生素的树状大分子纳米凝胶及其制备方法和应用

Resumen de: CN120732815A

本发明涉及一种外泌体包覆的共负载金纳米颗粒和抗生素的树状大分子纳米凝胶及其制备方法和应用，以树状大分子纳米凝胶为载体，载体内部共负载金纳米颗粒和药物，载体表面包裹外泌体。本发明操作条件简单，易于纯化，可改善抗生素的生物利用度并实现药物在病灶部位的靶向递送和响应性释放，在肺结核治疗中拥有良好的应用前景。

一种靶向放疗增敏剂、仿生纳米递送系统及其制备方法和应用

Resumen de: CN120733052A

本申请涉及生物医用纳米材料技术领域，公开了一种靶向放疗增敏剂、仿生纳米递送系统及其制备方法和应用。靶向放疗增敏剂的制备方法包括：将三苯基磷和多肽缩合剂溶于无水DMF中，搅拌均匀；再加入SH‑PEG2000‑NH2溶液进行反应，得到SH‑PEG2000‑TPP；将氯金酸溶液加热回流，再加入柠檬酸钠溶液，反应后得到AuNPs分散液；将AuNPs分散液、SH‑PEG2000‑NH2和SH‑PEG2000‑TPP混合反应，得到AuNP‑PEG2000‑TPP纳米粒子，即靶向放疗增敏剂。本申请的靶向放疗增敏剂进入肿瘤线粒体后，经过X射线照射，能够有效吸收射线能量，并转化为热能和电子激发能，产生活性氧(ROS)，进而激活炎性小体和caspase‑1，随后产生N端GSDMD蛋白片段，启动焦亡过程，发挥较强的放疗增敏作用；焦亡过程中释放IL‑1β和IL‑18等促炎细胞因子，进一步扩大局部的免疫反应。

一种罗汉果外泌体样纳米颗粒及其制备方法和在改善肠道健康产品中的应用

Resumen de: CN120732915A

本发明公开一种罗汉果外泌体样纳米颗粒及其制备方法和在改善肠道健康产品中的应用，将罗汉果果肉与预冷PBS匀浆，离心取上清液，经超速离心获得粗提液；通过羧基化磁珠偶联磷脂酰丝氨酸靶向多肽，构建免疫磁珠层析柱，特异性捕获并纯化外泌体样纳米颗粒；所得纳米颗粒具有优异的生物相容性和安全性，可显著调节肠道菌群平衡、增强肠道屏障功能、抑制肠道炎症；本发明为肠道疾病治疗及功能性食品开发提供了天然、高效的新方案，具有广阔的医药和食品应用前景。

一种负载葛花异黄酮的纳米颗粒及其制备方法和应用

Resumen de: CN120732816A

本发明公开了一种负载葛花异黄酮的纳米颗粒及其制备方法和应用，属于复合纳米颗粒技术领域。本发明的负载葛花异黄酮的纳米颗粒，包括纳米颗粒中心和多糖外壳；纳米颗粒中心为包覆葛花异黄酮的酒糟醇溶蛋白，多糖外壳由内至外依次为硫酸葡聚糖外壳和壳聚糖外壳。其制备方法包括以下步骤：以碳酸钠为牺牲模版制备负载葛花异黄酮的单层纳米颗粒；通过调节溶液pH，使纳米粒子带正电，以静电沉积效应涂覆负电性的硫酸葡聚糖外壳；然后与壳聚糖溶液混合，进一步涂覆正电性的壳聚糖外壳，形成层层自组装结构。本发明的负载葛花异黄酮的纳米颗粒在体外模拟消化环境中释放率更高，清除自由基活性更强，为葛花异黄酮的递送提供了更高效的技术。

一种可精准质控的干细胞纳米囊泡及其应用

Nº publicación: CN120738112A 03/10/2025

Solicitante:

南京赛立康生物医学科技有限公司

Resumen de: CN119530147A

The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.